Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

The first Pfizer-BioNTech COVID-19 vaccine dose in Canada sits ready for use at The Michener Institute in Toronto on Dec. 14, 2020.

Frank Gunn/The Canadian Press

British Columbia’s public-health officials are continuing to prioritize the delivery of second doses of its limited supply of COVID-19 vaccines, while it reviews a growing body of evidence that suggests it would be more effective to focus on first doses for more people.

Since vaccine supply began to arrive in December, British Columbia has administered 193,000 vaccines, including 37,000 second doses. The largest number of vaccines delivered in a single day in B.C. was on Thursday, with 12,251 people immunized. “More than half of those were second doses, reflecting the need to do that work,” Health Minister Adrian Dix said.

The BC Centre for Disease Control, or BCCDC, released two reports this week which conclude that the vaccines being used in Canada are more effective after a single dose than initially promised. Similar findings were published in The Lancet medical journal, based on a study of 9,000 health care workers from Israel, and in an analysis by the Institut national de santé publique du Québec. Both those reports were released Thursday.

Story continues below advertisement

As variants spread, modelling shows current public-health restrictions aren’t enough to stop a third wave of COVID-19

Ontario extends stay-at-home orders for Toronto, Peel as modelling warns of third wave

‘No runway left’: Retailers rattled as COVID-19 lockdowns extended in Toronto, Peel Region

The conclusions support the approach in Britain and in Quebec, where second doses are being delayed by up to 90 days – significantly longer than the manufacturers’ recommendations. British Columbia has already pushed back second doses to 42 days and has acknowledged that thousands of people will not receive their second dose within that window.

“We need to recognize that every time we administer a second dose to someone, we are depriving other high-risk individuals of that very substantial protection that they could have got from the first dose. It’s as straightforward as that,” Danuta Skowronski, lead for the influenza and emerging respiratory pathogens team at the BCCDC, said in an interview.

Dr. Skowronski is the lead author of a letter in the New England Journal of Medicine published Wednesday that says the two vaccines currently available in Canada are more effective than the manufacturers have estimated. An analysis found the Pfizer–BioNTech vaccine is 92.6-per-cent effective after the first dose, while Moderna’s vaccine was 92.1-per-cent effective after the first dose.

“Given the current vaccine shortage, postponement of the second dose is a matter of national security,” the article concludes. Adjusting vaccine plans to give priority to first doses will save lives, the research concludes.

“That’s absolutely a game-changer, because it says the second dose is adding very little to the protection that you are getting,” Dr. Skowronski said. “So what we are advocating, while the epidemic activity is still elevated and while the vaccine is in scarce supply, is that we more strategically deploy that limited vaccine to make sure we get at least a first dose into as many arms as possible, especially amongst those at high risk and our health care workers, before doubling back to make sure we top up an eenie-weenie bit of extra vaccine protection in those who have already got their first dose.”

As well, her research team found early vaccine effectiveness results within B.C. show the first dose of COVID-19 vaccine reduced the risk of infection in long-term care residents and health care workers by 80 per cent within two to three weeks of immunization. That is especially welcome news for residents of long-term care, who have accounted for the majority of COVID-10 deaths in the province.

Reka Gustafson, deputy provincial health officer, told reporters Friday there is an active debate about changing B.C.’s approach.

Story continues below advertisement

“What we’re trying to do is maximize the protection from the available vaccines to the entire population,” Dr. Gustafson said Friday. “I would say that the data are being looked at very, very carefully and evidence is accumulating to support that as a potential approach for maximizing protection in the population.”

The initial COVID-19 vaccinations in Canada and around the world raise questions about how people react to the shot, how pregnant women should approach it and how far away herd immunity may be. Globe health reporter Kelly Grant and science reporter Ivan Semeniuk discuss the answers. The Globe and Mail

We have a weekly Western Canada newsletter written by our B.C. and Alberta bureau chiefs, providing a comprehensive package of the news you need to know about the region and its place in the issues facing Canada. Sign up today.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow the author of this article:

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies